Ann: Recce Pharmaceuticals - Business Update, page-11

Please note exactly what the comment you point to means. Namely that the basis for the original comment (shown below in context) is that it is only necessary to administer R327 at MIC to kill 300 strains of ESKAPEE pathogens, even after repeated treatments. None develop resistance. This means that massive doses are not required to achieve overkill to prevent resistant strains taking over. This is good science, and an important fact for all to understand and grasp what is being said. This is something to celebrate I think.

R327 works and keeps on working with repeated use: tested in over 300 Strains of Bacterial Pathogens–Effective Against All

The Company continues to work with leading experts, dedicated to the discovery and development of innovative technologies, Linnaeus Bioscience, where they have tested R327 against over 300 strains between the ESKAPEE group of pathogens (198 Gram- negative and 111 Gram-positive bacteria strains). Chief Operations Officer Hannah Tsunemoto Ph.D. led the experiments against these pathogens and commented that: “R327 is effective against all strains tested at MICs”.

Gram-positive representatives

S. aureus

Gram-negative representatives

65A. baumannii53P. aeruginosa63Salmonella4E. coli40

Total 111

	Bacteria Strains
1	K. pneumoniae38

	Bacteria	Strains
1	Enterococcus spp.	33

	Enterobacter spp.	13

	Total	198

More than 95% of the strains tested were clinically isolated from a variety of sources, including but not limited to wounds, blood, urine and sputum (phlegm).

Furthermore, in a31-day sub-MIC serial exposure study, R327 was tested against a Multi-Drug Resistant (MDR) strain ofEscherichia coli (E. coli)andshowed no evidence of induced resistance to R327.